Levosimendan in Europe and China: An Appraisal of Evidence and Context

The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Xiangqing, Hu, Xinqun, Hua, Baotong, Fedele, Francesco, Farmakis, Dimitrios, Pollesello, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2021
Materias:
Heart Failure
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591618/
https://www.ncbi.nlm.nih.gov/pubmed/34815750
http://dx.doi.org/10.15420/ecr.2021.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591618/
https://www.ncbi.nlm.nih.gov/pubmed/34815750
http://dx.doi.org/10.15420/ecr.2021.41

Ejemplares similares